The drugmaker expects to submit the vaccine’s application for FDA emergency use authorization by the end of 2021.
The study also found the vaccine was 100 percent effective at preventing moderate and severe disease.
The data came from a phase 3 trial that took place from Dec. 27, 2020, to Feb. 18, 2021, and enrolled 29,960 participants across 119 sites in the U.S. and Mexico.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.